Holen Sie sich die Stockscreener-App
24.43
1.79%
0.4299
Handel nachbörslich:
24.43
0.000100
+0.00%
Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - TipRanks
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - GlobeNewswire Inc.
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - Sahm
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 512.5% - MarketBeat
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - markets.businessinsider.com
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
LENZ Therapeutics (LENZ) Receives a Buy from Piper Sandler - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):